Every 424B that Solana Company (HSDT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow HSDT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HSDT filings page.
Solana Company is offering shares of Class A common stock having an aggregate offering price of up to $250,000,000 pursuant to an amended and restated sales agreement with Clear Street LLC and Maxim Group LLC dated May 29, 2026.
The offering may be made from time to time as an at‑the‑market (ATM) program or by negotiated transactions; sales agents may receive up to 3.0% of gross proceeds. The company intends to use net proceeds, together with existing cash, to accumulate SOL tokens, for working capital and general corporate purposes. The prospectus supplement states 177,510,127 shares would be outstanding after an illustrative sale based on an assumed price of $2.04 per share.
Solana Company is selling 3,076,922 shares of Class A common stock in a registered direct offering at $2.60 per share for a total offering price of $7,999,997.20, with delivery expected on or about April 28, 2026.
The company expects net proceeds of approximately $7.9 million to be used for accumulating SOL, working capital, general corporate purposes, business expansion and strategic initiatives. The offering is made under a Form S-3 shelf registration and assumes no exercise of outstanding warrants.
Solana Company has filed a prospectus supplement to update the list of selling stockholders for an existing resale registration. The registration covers up to 37,679,950 shares of Class A common stock issued in PIPE offerings, 36,261,239 shares of common stock underlying pre-funded warrants with a per share exercise price of $0.001, 73,941,189 shares of common stock underlying stapled warrants with an exercise price of $10.134 per share, and 7,394,119 shares of common stock underlying advisor warrants with a per share exercise price of $0.001. The supplement replaces prior information for certain holders and confirms their beneficial ownership positions. Shares outstanding were 158,071,453 as of November 13, 2025; this is a baseline figure, not the amount being offered.
Helius Medical Technologies filed a prospectus supplement for an at-the-market equity program to sell up to $92.8 million of Class A common stock and disclosed a contemporaneous PIPE (cash and cryptocurrency) and advisory agreements dated September 15, 2025. The company reported a last Nasdaq sale price of $7.56 per share and expects the PIPE to close on or about September 18, 2025, subject to customary conditions and stockholder approvals for certain warrants.
Management intends to use net proceeds primarily to acquire SOL (Solana) tokens and to support a Solana-centric digital asset treasury, with Pantera engaged as strategic and trading advisor. The filing discloses recent corporate actions including reverse stock splits, increases in authorized shares, prior private placements and Nasdaq compliance remediation; Nasdaq confirmed regained compliance but the company will be monitored until July 7, 2026. The supplement emphasizes significant regulatory, custody, staking and market risks tied to the Solana strategy and potential dilution from multiple warrant and financing arrangements.